FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2159831986> ?p ?o ?g. }

• W2159831986 endingPage "914" @default.
• W2159831986 startingPage "906" @default.
• W2159831986 abstract "ObjectiveThis multicenter, prospective, nonrandomized trial was undertaken to evaluate the first-in-human experience with the INCRAFT endograft (Cordis Corporation, Bridgewater, NJ), an ultralow-profile trimodular bifurcate device for the repair of abdominal aortic aneurysms.MethodsPatients with asymptomatic infrarenal abdominal aortic aneurysms were eligible for enrollment in the trial. Anatomic eligibility criteria included a proximal aortic neck at least 15 mm in length and up to 27 mm in diameter, and an aortic bifurcation ≥18 mm in diameter. Iliofemoral access vessels were required to be large enough to accept the 14F (4.7 mm) outer diameter of the delivery system. The primary efficacy end point was technical success, defined by successful device deployment during the conclusion of the procedure at the desired location without a type I, III, or IV endoleak. The primary safety end point was defined by the absence of a type I, III, or IV endoleak or a device- or procedure-related major adverse event at the 1-month follow-up point.ResultsOver a 16-month period divided into two different phases, 57 men and three women with a mean age of 74.4 ± 6.9 years were enrolled at three German and three Italian centers. A percutaneous approach was used in 36 patients (60%). Successful graft deployment at the desired location was achieved in 59 patients (98%). A single patient had successful deployment of the device although it was located more distally than planned. Technical success was achieved in 54 patients (90%); one patient had a type I endoleak, four had type IV endoleaks, and one had an endoleak of undetermined origin. The primary safety end point was met in 56 of the 58 patients (97%) with complete core laboratory data at 1 month; two patients had type I endoleaks. There were no type III or IV endoleaks and no device or procedure-related major adverse events at 1 month. No limb thromboses or stent fractures were noted on postoperative imaging studies and no patient required rehospitalization, a secondary procedure, or open surgical conversion through 1 month of follow-up.ConclusionsThe INCRAFT endograft device holds promise as an innovative alternative to currently marketed devices and broadens the eligibility for endovascular aneurysm repair. More definitive observations will be generated as longer-term data from this trial become available. This multicenter, prospective, nonrandomized trial was undertaken to evaluate the first-in-human experience with the INCRAFT endograft (Cordis Corporation, Bridgewater, NJ), an ultralow-profile trimodular bifurcate device for the repair of abdominal aortic aneurysms. Patients with asymptomatic infrarenal abdominal aortic aneurysms were eligible for enrollment in the trial. Anatomic eligibility criteria included a proximal aortic neck at least 15 mm in length and up to 27 mm in diameter, and an aortic bifurcation ≥18 mm in diameter. Iliofemoral access vessels were required to be large enough to accept the 14F (4.7 mm) outer diameter of the delivery system. The primary efficacy end point was technical success, defined by successful device deployment during the conclusion of the procedure at the desired location without a type I, III, or IV endoleak. The primary safety end point was defined by the absence of a type I, III, or IV endoleak or a device- or procedure-related major adverse event at the 1-month follow-up point. Over a 16-month period divided into two different phases, 57 men and three women with a mean age of 74.4 ± 6.9 years were enrolled at three German and three Italian centers. A percutaneous approach was used in 36 patients (60%). Successful graft deployment at the desired location was achieved in 59 patients (98%). A single patient had successful deployment of the device although it was located more distally than planned. Technical success was achieved in 54 patients (90%); one patient had a type I endoleak, four had type IV endoleaks, and one had an endoleak of undetermined origin. The primary safety end point was met in 56 of the 58 patients (97%) with complete core laboratory data at 1 month; two patients had type I endoleaks. There were no type III or IV endoleaks and no device or procedure-related major adverse events at 1 month. No limb thromboses or stent fractures were noted on postoperative imaging studies and no patient required rehospitalization, a secondary procedure, or open surgical conversion through 1 month of follow-up. The INCRAFT endograft device holds promise as an innovative alternative to currently marketed devices and broadens the eligibility for endovascular aneurysm repair. More definitive observations will be generated as longer-term data from this trial become available." @default.
• W2159831986 created "2016-06-24" @default.
• W2159831986 creator A5000066434 @default.
• W2159831986 creator A5006083917 @default.
• W2159831986 creator A5008255012 @default.
• W2159831986 creator A5028263534 @default.
• W2159831986 creator A5047520967 @default.
• W2159831986 creator A5049272326 @default.
• W2159831986 creator A5082916850 @default.
• W2159831986 creator A5086687189 @default.
• W2159831986 date "2013-04-01" @default.
• W2159831986 modified "2023-09-29" @default.
• W2159831986 title "First-in-human study of the INCRAFT endograft in patients with infrarenal abdominal aortic aneurysms in the INNOVATION trial" @default.
• W2159831986 cites W1969986918 @default.
• W2159831986 cites W1996046620 @default.
• W2159831986 cites W2012332577 @default.
• W2159831986 cites W2012676952 @default.
• W2159831986 cites W2017650214 @default.
• W2159831986 cites W2017981408 @default.
• W2159831986 cites W2028477410 @default.
• W2159831986 cites W2029792537 @default.
• W2159831986 cites W2030346221 @default.
• W2159831986 cites W2034919409 @default.
• W2159831986 cites W2045572533 @default.
• W2159831986 cites W2046690456 @default.
• W2159831986 cites W2055891585 @default.
• W2159831986 cites W2065774098 @default.
• W2159831986 cites W2070228565 @default.
• W2159831986 cites W2086947471 @default.
• W2159831986 cites W2089857314 @default.
• W2159831986 cites W2090099381 @default.
• W2159831986 cites W2093824562 @default.
• W2159831986 cites W2098220172 @default.
• W2159831986 cites W2100850234 @default.
• W2159831986 cites W2109761253 @default.
• W2159831986 cites W2112261347 @default.
• W2159831986 cites W2116162678 @default.
• W2159831986 cites W2117926134 @default.
• W2159831986 cites W2140579637 @default.
• W2159831986 cites W2140989807 @default.
• W2159831986 cites W2141908194 @default.
• W2159831986 cites W2143296285 @default.
• W2159831986 cites W2148782056 @default.
• W2159831986 cites W2153972853 @default.
• W2159831986 cites W2156798468 @default.
• W2159831986 cites W2165498862 @default.
• W2159831986 cites W4236425530 @default.
• W2159831986 cites W4243963849 @default.
• W2159831986 doi "https://doi.org/10.1016/j.jvs.2012.09.079" @default.
• W2159831986 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23332982" @default.
• W2159831986 hasPublicationYear "2013" @default.
• W2159831986 type Work @default.
• W2159831986 sameAs 2159831986 @default.
• W2159831986 citedByCount "18" @default.
• W2159831986 countsByYear W21598319862013 @default.
• W2159831986 countsByYear W21598319862014 @default.
• W2159831986 countsByYear W21598319862015 @default.
• W2159831986 countsByYear W21598319862016 @default.
• W2159831986 countsByYear W21598319862017 @default.
• W2159831986 countsByYear W21598319862019 @default.
• W2159831986 countsByYear W21598319862020 @default.
• W2159831986 countsByYear W21598319862021 @default.
• W2159831986 countsByYear W21598319862022 @default.
• W2159831986 countsByYear W21598319862023 @default.
• W2159831986 crossrefType "journal-article" @default.
• W2159831986 hasAuthorship W2159831986A5000066434 @default.
• W2159831986 hasAuthorship W2159831986A5006083917 @default.
• W2159831986 hasAuthorship W2159831986A5008255012 @default.
• W2159831986 hasAuthorship W2159831986A5028263534 @default.
• W2159831986 hasAuthorship W2159831986A5047520967 @default.
• W2159831986 hasAuthorship W2159831986A5049272326 @default.
• W2159831986 hasAuthorship W2159831986A5082916850 @default.
• W2159831986 hasAuthorship W2159831986A5086687189 @default.
• W2159831986 hasBestOaLocation W21598319861 @default.
• W2159831986 hasConcept C126322002 @default.
• W2159831986 hasConcept C126838900 @default.
• W2159831986 hasConcept C141071460 @default.
• W2159831986 hasConcept C168563851 @default.
• W2159831986 hasConcept C188816634 @default.
• W2159831986 hasConcept C197934379 @default.
• W2159831986 hasConcept C203092338 @default.
• W2159831986 hasConcept C2776098176 @default.
• W2159831986 hasConcept C2777323849 @default.
• W2159831986 hasConcept C2777910003 @default.
• W2159831986 hasConcept C2779980429 @default.
• W2159831986 hasConcept C2779993416 @default.
• W2159831986 hasConcept C2780015500 @default.
• W2159831986 hasConcept C2780813298 @default.
• W2159831986 hasConcept C71924100 @default.
• W2159831986 hasConceptScore W2159831986C126322002 @default.
• W2159831986 hasConceptScore W2159831986C126838900 @default.
• W2159831986 hasConceptScore W2159831986C141071460 @default.
• W2159831986 hasConceptScore W2159831986C168563851 @default.
• W2159831986 hasConceptScore W2159831986C188816634 @default.
• W2159831986 hasConceptScore W2159831986C197934379 @default.
• W2159831986 hasConceptScore W2159831986C203092338 @default.
• W2159831986 hasConceptScore W2159831986C2776098176 @default.
• W2159831986 hasConceptScore W2159831986C2777323849 @default.

• next